Drug Index

Miglustat

Mechanism :

Miglustat competitively and reversibly inhibits the enzyme needed to produce glycosphingolipids and decreases the rate of glycosphingolipid glucosylceramide formation.


Indication :

  • Gaucher disease (adults only)
  • Off-label: Niemann-Pick Type C disease

Contraindications :

Hypersensitivity to miglustat or any component of the formulation; women who are or may become pregnant.


Dosing :

Oral:
<12 years
BSA >1.25 m²: 200 mg 3 times daily.
BSA >0.88 to 1.25 m²: 200 mg 2 times daily.
BSA >0.73 to 0.88 m²: 100 mg 3 times daily.
BSA >0.47 to 0.73 m²: 100 mg 2 times daily.
BSA ≤0.47 m²: 100 mg once daily.
≥12 years
200 mg 3 times daily.

Adverse Effect :

Headache, dizziness, weight loss, diarrhea, abdominal pain, vomiting, tremor, weakness, leg cramps, visual disturbance, unsteady gait, paresthesia, abdominal distension, thrombocytopenia, back pain.


Interaction :

No known significant interactions.



Hepatic Dose :

No dose adjustments are recommended.
02/16/2021 04:43:21 Miglustat
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0